FDA Clears Tevogen Bio’s IND Application for CTL COVID-19 Treatment
The IND for Tevogen Bio's TVGN-489, an allogeneic COVID-19-specific cytotoxic T lymphocyte, received rapid clearance from FDA.
FDA cleared Tevogen Bio’s investigational new drug application for its investigational COVID-19 treatment, TVGN-489, which is an allogeneic COVID-19-specific cytotoxic T lymphocyte (CTL), the company announced on July 12, 2021.
This clearance allows Tevogen Bio to begin clinical trials, which will evaluate the safety of TVGN-489 in high-risk COVID-19 patients and will also measure viral load and long-term immune response as secondary endpoints. In addition, the results of the patients receiving TVGN-489 will be compared to patients treated with the current standard of care. The previous preclinical study for TVGN-489 demonstrated strong antiviral activity against SARS-CoV-2.
Programmed to detect targets from the entire viral genome, TVGN-489 is highly purified SARS-CoV-2 specific cytotoxic CD8+ T lymphocytes. The CTLs are anticipated to detect and kill virus-infected cells, which then allows the body to replace them with healthy, uninfected cells.
Source: Tevogen Bio, Business Wire
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
